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ABSTRACT 
Adrenal insufficiency continues to present a challenge for patients, their physicians and 
researchers. Over the last decade, long-term health outcome studies highlighted the increased 
rates of mortality, morbidity and impaired quality of life in patients with adrenal insufficiency.  
This may be at least partially due to our failure to deliver glucocorticoid replacement therapy that 
closely resembles physiological diurnal cortisol secretion. The potential impact of newly 
developed glucocorticoid preparations is a focus of current research as are the mechanisms 
potentially underlying the increased morbidity and mortality. Adrenal crisis remains a threat and 
increasing awareness and preventative measures are parts of clinical management of adrenal 
insufficiency that receive increasing attention.  
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INTRODUCTION 
Adrenal insufficiency is caused by failure of the adrenal cortex to produce cortisol. This can 
result from loss of function of the adrenal glands, i.e. primary adrenal insufficiency, most 
frequently caused by autoimmune adrenalitis (“Addison’s disease”) and inborn disruption of 
glucocorticoid synthesis by congenital adrenal hyperplasia1-4. Secondary adrenal insufficiency is 
caused by impaired hypothalamic-pituitary regulation of adrenal cortisol synthesis, mostly caused 
by tumours of the hypothalamic-pituitary region and their treatment by surgery or radiotherapy5. 
However, chronic exogenous glucocorticoid treatment also invariably causes adrenal 
insufficiency, with potential reversibility following gradual withdrawal. 
The clinical phenotype of primary adrenal insufficiency was first described by Thomas Addison 
in 18556, a fatal disease until corticosteroid replacement became available. Two years after 
Edward Kendall first isolated corticosterone in 1936, Simpson used synthetic deoxycorticosterone 
acetate in the treatment of Addison’s disease with success7. However, widespread availability of 
glucocorticoids was only achieved by the synthesis of cortisone, transforming the life of patients 
with rheumatoid arthritis8 and prompting the award of the Nobel Prize in Medicine to Kendall, 
Philip Hench and Tadeusz Reichstein in 1950.  
Today, despite these achievements, adrenal insufficiency continues to present significant 
challenges regarding diagnosis, optimised replacement therapy and long-term health outcomes 
including quality of life and mortality. This review represents a comprehensive update of our last 
major review9, focussing on controversies and new developments. 
 
SEARCH STRATEGY 
We conducted a comprehensive search of several databases including Ovid Medline In-Process & 
Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register 
of Controlled Trials, and Ovid Cochrane Database of Systematic Reviews. Search terms included 
adrenal insufficiency, hypoadrenalism, adrenal hypofunction, Addison's disease, 
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adrenoleukodystrophy, and hypoaldosteronism. Case reports, letters and commentaries were 
excluded. We selected all relevant articles in English published from January 2003 to March 2014 
to capture developments since publication of our last comprehensive review9.  
 
CAUSES OF ADRENAL INSUFFICIENCY 
Causes of primary adrenal insufficiency  
In developed countries, autoimmune-mediated adrenalitis with subsequent destruction of adrenal 
tissue is the most common cause of primary adrenal insufficiency, accounting for 68-94% of 
cases10; it can occur in isolation (30-40%) or in combination with other autoimmune diseases as 
part of autoimmune polyglandular syndromes (APS) type 1 (10-15%) and type 2 (50-60%) (Table 
1). APS1 (or APECED, autoimmune polyendocrinopathy with adrenal insufficiency and 
hypoparathyroidism, mucocutaneous candidiasis, ectodermal dystrophy) is a monogenic disease, 
caused by mutations in the autoimmune regulator gene AIRE, while several disease susceptibility 
genes have been identified for APS2 and isolated Addison’s disease (CTLA4, PTPN22, MICA 
5.1)11. The latter are also associated with distinct alleles and haplotypes within the major 
histocompatibility complex human leukocyte antigen (HLA) including DR3-DQ2, DR4-DQ8 and 
DRB1 0301 and 040411.12.   
The most frequent monogenic cause of adrenal insufficiency is congenital adrenal hyperplasia, 
which is identical in prevalence to autoimmune adrenalitis (Table 1).  Congenital adrenal 
hyperplasia is caused by mutations in enzymes involved in glucocorticoid synthesis, most 
commonly (~95%) due to mutations in the CYP21A2 gene encoding 21-hydroxylase, with an 
incidence of 1:12,000 to 1:15,000 in most populations.  
Adrenoleukodystrophy is an X-linked disorder caused by mutations in the ABCD1 gene that 
encodes for a peroxisomal transporter protein, resulting in defective oxidation of very long chain 
fatty acids and their accumulation in various tissues, most notably in brain and adrenal cortex. 
Clinically, adrenoleukodystrophy presents with very different phenotypes: cerebral 
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adrenoleukodystrophy, with childhood onset and rapid progression of neurodegeneration, and 
adrenomyeloneuropathy, presenting in late adolescence and adulthood with spinal and peripheral 
neuropathy. Adrenal insufficiency can precede neurological symptoms or even represent the only 
manifestation; identical mutations might result in very variable penetrance and phenotypes within 
affected families. 
Other, rarer causes of primary adrenal insufficiency are summarised in Table 1. 
 
Causes of secondary adrenal insufficiency  
Any process destroying normal pituitary or hypothalamic tissue can lead to ACTH deficiency and 
consequent loss of stimulation of adrenal cortisol synthesis. Pituitary adenomas are the most 
frequently encountered pathology 13. However, other hypothalamic-pituitary tumours, such as 
craniopharyngiomas, meningiomas, and intra- and suprasellar metastases can also cause 
secondary adrenal insufficiency. Rarer causes (Table 1) are traumatic brain injury, infection and 
infiltration of the pituitary and all acquired and most inherited causes of secondary adrenal 
insufficiency can also result in loss of function of other hypothalamic-pituitary axes.  
 
Drug-induced adrenal insufficiency  
Numerous drugs can result in decreased cortisol synthesis, increased cortisol inactivation or 
impaired glucocorticoid action (Table 1). The most common cause of drug-induced adrenal 
insufficiency is the suppression of the hypothalamic-pituitary-adrenal axis by exogenous 
glucocorticoid doses ≥5mg prednisolone equivalent for more than four weeks, irrespective of 
mode of delivery (topical, inhaled, oral or injected). Similarly, patients with Cushing’s syndrome 
are rendered adrenal insufficient by successful treatment of the endogenous cortisol excess. 
Recovery of the hypothalamic-pituitary adrenal axis can take many months and time to recovery 
corresponds to some degree with the preceding period of glucocorticoid excess14, 15.  
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The enzyme CYP3A4 is responsible for metabolism of 80% of drugs and xenobiotics including 
all steroids. CYP3A4 inactivates cortisol to 6β-hydroxycortisol; consequently CYP3A4 inducers 
result in rapid inactivation of cortisol and to compensate for this, patients may require increased 
glucocorticoid replacement doses16. 
 
CLINICAL PRESENTATION 
Presenting signs and symptoms in primary adrenal insufficiency are often unspecific, explaining 
the often significant delay in diagnosis, in many patients only established after acute 
hospitalization with adrenal crisis4, 17.  According to four larger series4, 11, 22, 23, signs and 
symptoms comprise fatigue (84-95%), loss of appetite (53-67%), weight loss (66-76%), nausea, 
vomiting and abdominal pain (49-62%), and muscle and joint pain (36-40%). More specific signs 
and symptoms are skin hyperpigmentation (41-74%), resulting from enhanced activation of skin 
melanocortin 1 receptors (MC1R) by high ACTH, and salt craving (38-64%) and postural 
hypotension (55-68%) due to mineralocorticoid deficiency. Hyponatraemia (70-80%) is the most 
common laboratory abnormality, followed by hyperkalaemia (30-40%) and normochromic 
anaemia (11-15%)4, 10, 17. Family history of autoimmune disease is reported by every third 
patient18, 19, though rarely including Addison’s disease (generally 2%11; 10% in Norwegians4). 
In secondary adrenal insufficiency the mineralocorticoid axis is intact, thus postural hypotension 
and electrolyte abnormalities are less frequent17. However, hyponatraemia can be observed due to 
decreased inhibitory control of vasopressin secretion20, effectively resulting in mild SIADH. 
Hyperpigmentation is absent due to reduced stimulation of skin MC1R by ACTH, giving the skin 
an alabaster-like appearance. In addition, other pituitary axes and also vision due to compression 
of the optic chiasm may be compromised.  
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DIAGNOSIS OF ADRENAL INSUFFICIENCY 
Confirmation of Adrenal Insufficiency 
The ACTH stimulation test, also termed short synacthen test or cosyntropin test, is commonly 
used for the diagnosis of adrenal insufficiency and can be performed at any time of the day by 
drawing blood for serum cortisol at baseline and 30 or 60 minutes after parenteral administration 
of 250µg of ACTH1-24 (synacthen®). Some have championed the use of the so-called low dose 
ACTH test employing 1µg of ACTH; however, this still represents a supraphysiological stimulus 
and no advantage of this test has been demonstrated convincingly21; in addition, commercially 
available ACTH ampoules contain 250µg ACTH1-24, rendering a dilution impractical and too 
inaccurate for routine use.  
Cortisol response to ACTH is slightly higher at 60 than at 30 min22, but there are no documented 
advantages in sensitivity and specificity for the use of either time-point. The exact diagnostic cut-
offs depend on assay-specific local reference ranges and are usually set at 500-550 nmol/L (18-20 
µg/dl) after ACTH stimulation.  
Cortisol secretion follows a characteristic diurnal rhythm, rising in the early morning hours (2-
4am), peaking in the morning (6-9 a.m.) and then descending to low levels in the evening and 
very low levels around midnight23. Random morning cortisol levels <80nmol/L (3µg/dl) are 
strongly predictive of adrenal insufficiency24.  However, to safely establish the diagnosis of 
adrenal insufficiency, an ACTH stimulation test should always be performed. Importantly, 
diagnostic tests should never delay the prompt initiation of life-saving hydrocortisone treatment 
in suspected adrenal crisis; formal confirmation of diagnosis can be safely carried out after 
clinical recovery. 
Measurement of plasma ACTH is the mandatory first step in the differential diagnosis of adrenal 
insufficiency (Figure 1).  In primary adrenal insufficiency, ACTH levels are usually >100pg/mL 
(22pmol/L)25; plasma renin will also be elevated, with concomitantly low serum aldosterone. In 
secondary adrenal insufficiency, ACTH levels will be low or inappropriately normal while 
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mineralocorticoid secretion is sufficient. Serum DHEAS will be invariably low in both primary 
and secondary adrenal insufficiency. 
In secondary adrenal insufficiency, where adrenal atrophy ensues from lack of endogenous 
ACTH stimulation, the short synacthen test is also generally useful. However, within four weeks 
of a pituitary insult/surgery the adrenal glands are not yet atrophied and thus will still be 
responsive to ACTH, which could wrongly indicate an intact HPA axis. Early postoperative 
morning cortisol levels >275nmol/L (10µg/dl) were shown to be an accurate predictor of a normal 
corticotroph reserve26, 27.  The long-term predictive value of short synacthen test cut-offs of 510 
and 550nmol/L were evaluated retrospectively in a large cohort of patients investigated for 
secondary adrenal insufficiency and demonstrated a very low incidence of false negative results 
(2/178 patients)28.  
The insulin tolerance test is the gold standard for diagnosis of secondary adrenal insufficiency but 
the testing procedure is cumbersome, expensive to carry out and can be unsafe in patients with 
history of seizures and cardiac disease; special care should be taken if the test is carried out in 
children or elderly patients. Achieving or failing to achieve an adequate hypoglycaemia (2.2 
mmol/L (<40 mg/dl)) are additional limiting factors. Usually 0.1U insulin per kg body weight is 
used, however around a third of patients need more29. Peak cortisol levels <500nmol/L (18µg/dl) 
are considered diagnostic for adrenal insufficiency30. 
 
DIFFERENTIAL DIAGNOSIS AND CONFIRMATION OF ETIOLOGY 
In primary adrenal insufficiency, increased antibody titres against 21-hydroxylase and adrenal 
cortex are indicators of autoimmune adrenalitis31, the most frequent cause of disease once 
congenital adrenal hyperplasia is ruled out. Therefore measurement of relevant auto-antibodies is 
the logical first step in differential diagnosis. If neither the family history nor antibody titre point 
toward autoimmune pathogenesis, then further investigations should be undertaken (Figure 1). 
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However, autoimmune adrenalitis is still the most likely underlying cause as many patients turn 
antibody negative when autoimmune destruction has progressed for some time. 
Screening for congenital adrenal hyperplasia in adults with adrenal insufficiency consists of 
serum 17-hydroxyprogesterone at baseline and after ACTH. In antibody-negative patients, 
adrenal imaging is helpful and can reveal infiltrative processes, infection or haemorrhage. 
Bilateral metastases of solid organ tumours such as lung, breast and kidney are associated with an 
increased risk of adrenal insufficiency32 ; therefore such patients should undergo screening by a 
short synacthen test. In antibody-negative men, screening for plasma very long chain fatty acids 
should be carried out, to exclude adrenoleukodystrophy, even if no neurological signs are present. 
In secondary adrenal insufficiency, MRI imaging of the hypothalamic-pituitary area is the first 
point of call. Pituitary incidentalomas are frequent and unlikely to cause adrenal insufficiency 
unless >1 cm; thus pituitary imaging is only warranted if plasma ACTH is low or inappropriately 
normal and cortisol fails to respond appropriately to ACTH. Review of medications should 
include recent use of topical and intra-articular corticosteroid preparations and over-the-counter 
supplements. 
 
SPECIAL DIAGNOSTIC SITUATIONS 
Adrenal crisis, hospital admission: If acute adrenal insufficiency is clinically suspected, 
hydrocortisone should be administered without delay (100mg bolus injection, followed by 200mg 
per 24 hours either as a continuous infusion or 50mg every 6 hours) along with intravenous fluid 
resuscitation. If possible, blood samples for paired cortisol and ACTH can be drawn beforehand 
and in haemodynamically stable patients also a short synacthen test can be performed; however, if 
in doubt, it is better to treat promptly and confirm the diagnosis later after the patient is better.  
Increased or reduced corticosteroid-binding globulin concentrations: More than 90% of 
circulating cortisol is bound to corticosteroid binding globulin (CBG) and only the remaining free 
fraction is biologically active33. Although not routinely advocated, there are special circumstances 
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in which measurement of serum free cortisol and/or CBG may be useful. CBG is decreased 
during acute illness, in severe liver disease and in the rare patients with CBG gene mutations. 
Enhanced oestrogen action, e.g. during pregnancy or intake of oral contraceptives, significantly 
increases CBG, resulting in increased total cortisol but unchanged free cortisol. The latter is not 
routinely measured and studies on normal reference values in pregnancy are currently lacking. 
Data on the utility of salivary cortisol are too limited for firm recommendations34, 35. 
Patients on exogenous steroids: Current or recent exogenous glucocorticoid therapy can 
complicate interpretation of ACTH test results. Careful review of treatment history during the last 
12 months (including administration of topical, inhaled, intranasal, epidural or intra-articular 
preparations) is essential. A further important consideration is the possibility that some synthetic 
glucocorticoids can cross-react with the immunoassays used to measure circulating cortisol in 
many routine biochemistry laboratories36.  
Assessing the adequacy of adrenal reserve in patients who are undergoing planned withdrawal of 
chronic exogenous glucocorticoid treatment can be challenging37. Supraphysiological 
glucocorticoid therapy causes adrenal atrophy that is slowly reversible in the majority of cases. 
However, there is considerable inter-individual variability in the degree of hypothalamic-
pituitary-adrenal axis suppression and the time to recovery14. Glucocorticoids should be slowly 
tapered and if there is no ongoing indication for glucocorticoid therapy other than adrenal 
insufficiency, long-acting glucocorticoids should ideally be switched to hydrocortisone. 
Assessment of adrenal function can be undertaken after hydrocortisone has been temporarily 
stopped for 24 hours prior to ACTH1-24 stimulation testing. Prednisone, prednisolone and 
dexamethasone may impact on results for at least 48-72 hours if not longer, hence switching to 
hydrocortisone prior to comprehensive testing of adrenal reserve is often more prudent.   
All modes of glucocorticoid administration (oral, inhaled, intranasal, topical, intra-articular, intra-
muscular and intra-venous) have been associated with hypothalamic-pituitary-adrenal axis 
suppression, which may be present in half of the patients taking inhaled glucocorticoid therapy38-
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40, though the true magnitude of this problem and the clinical consequences are still largely 
unknown and data on optimised diagnostic work-up are limited. If there are signs and symptoms 
suggestive of adrenal insufficiency, dynamic assessment of adrenal reserve should be undertaken, 
but routine screening in all patients on inhaled, topical or intranasal therapy is not recommended. 
Often, it is not possible to omit glucocorticoid therapy, even for a short period of time (inhaled 
glucocorticoids for asthma), further complicating the assessment. It is important to take a multi-
disciplinary team approach to clarify whether supraphysiological glucocorticoid therapy is still 
required or whether glucocorticoids can be carefully tapered. Management can be complex and a 
balance between the prevention of adrenal crisis and minimizing glucocorticoid excess.  
 
CHRONIC REPLACEMENT THERAPY 
Glucocorticoid replacement 
Daily physiological production of cortisol is around 5-6 mg/m2 body surface area41. Currently 
recommended hydrocortisone doses are 15-25 mg, usually administered in two to three daily 
doses, with 50-66% of the daily dose administered in the morning upon awakening9. The second 
dose is usually administered 6-8 hours after the morning dose; if a thrice daily regimen is 
followed the second dose is administered 4-6 hours after the early morning dose and the third 
dose 4-6 hours thereafter. Some recommend weight-adjusted dosing to achieve reduction in 
intervals of excess in cortisol levels during the day and decreased variability of cortisol profiles42. 
Decision on number of doses is also based on patient preference, differences in daily activity and 
experience. 
As there is no reliable biochemical marker to assess the appropriateness of glucocorticoid 
replacement dose, dose modification is guided by clinical judgment, subjective perception of 
symptoms and signs and symptoms of glucocorticoid under- and over-replacement, respectively. 
The goal is to achieve the best clinical result with the lowest possible daily dose of steroid. 
Cortisol day curves are of limited value in routine monitoring43. In our experience, timed 
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measurement of serum cortisol is only of value if malabsorption or increased metabolic clearance 
is suspected. Monitoring plasma ACTH is not useful. Urinary 24-h free cortisol excretion shows 
considerable inter-individual variability and comparison to normal reference ranges are not useful  
as due to the pharmacokinetic properties of current glucocorticoid preparations the kidney 
excretion threshold is much more quickly overcome after exogenous administration of 
glucocorticoids. 
A global survey of more than 1000 patients with mostly primary adrenal insufficiency revealed 
that hydrocortisone is most commonly used (75%), followed by prednisone/prednisolone (11%), 
cortisone acetate (6%) and dexamethasone (4%)44. Cortisone acetate (1.6 hydrocortisone 
equivalent) and prednisone (0.25 hydrocortisone equivalent) require intrahepatic activation to 
cortisol and prednisolone (0.20mg hydrocortisone equivalent), respectively, by 11β-
hydroxysteroid dehydrogenase type 1, which might lead to a higher pharmacokinetic variability 
compared to hydrocortisone. The long-lasting synthetic steroids prednisone and dexamethasone 
(0.025 hydrocortisone equivalent) exert strong anti-inflammatory action and hence are frequently 
used in chronic inflammatory conditions.   
Over the last few years progress has been made in the development of steroid preparations aiming 
to provide a more circadian-based serum cortisol profile23. This was pioneered by the 
demonstration of superior biochemical control as well as indications of improved quality of life in 
adrenal insufficiency patients receiving intravenous and subcutaneous hydrocortisone infusions45. 
An approved option for modified release oral hydrocortisone is Duocort that provides longer 
acting delivery of hydrocortisone, however, fails to resurrect physiologic early morning secretion 
of cortisol. An early rise in morning cortisol can be achieved by modified and delayed release 
glucocorticoid preparations, such as prednisone delayed-release tablets and, possibly more 
physiologically, by the modified and delayed release hydrocortisone preparation Chronocort that 
is currently under development23, 46. However, data from larger clinical trials on the beneficial 
impact of these newer preparations in patients with adrenal insufficiency are currently still 
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lacking. We recommend an individualized approach based on clinical symptoms and signs, 
patient’s circumstances and preferences. 
 
Mineralocorticoid replacement 
Fludrocortisone (9-alpha-fluor-cortisol) is used for mineralocorticoid replacement as a single 
morning dose, usually between 50-300µg, with a typical starting dose of 100-150µg. Electrolytes 
within the normal range, blood pressure without a significant postural drops and plasma renin 
concentrations/activity in the upper normal range serve as indicators of adequate 
mineralocorticoid replacement. Hydrocortisone also exerts mineralocorticoid activity, with 40mg 
hydrocortisone equivalent to 100µg fludrocortisone25. Thus, changes in hydrocortisone dose may 
impact on fludrocortisone dose requirements. Prednisolone has some and dexamethasone has 
absolutely no mineralocorticoid activity. 
Fludrocortisone requirements are monitored by serum sodium and potassium and plasma renin, 
the latter should range in the upper normal reference range. The presence of salt craving, 
dizziness and postural hypotension could be indicative of underreplacement, while peripheral 
oedema and new-onset arterial hypertension could indicate overreplacement. Fludrocortisone 
dose requires increasing in case of enhanced salt loss through perspiration, e.g. due to physical 
activity or a hot climate. 
 
Adrenal androgen precursor replacement: 
In women, androgen production by the adrenal glands is the main source of androgens; therefore, 
adrenal insufficiency is invariably associated with severe androgen deficiency in women. Serum 
DHEAS concentrations physiologically peak between 20-30 years, followed by a gradual 
decline47 that is independent of menopause. The adrenal androgen precursor 
dehydroepiandrosterone, DHEA, is activated to sex steroids in a wide variety of peripheral tissues 
and in the gonads, but has also neurosteroidal activity in the brain.  DHEA supplementation in 
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adrenal insufficiency has been shown to improve overall wellbeing48-51, depression and anxiety 
scores 48, 52 and sexual interest and satisfaction48 in some trials, but not all . The benefit of DHEA 
replacement is likely to be more significant in women of premenopausal age51.  A trial of DHEA 
could be considered in particular in women with adrenal insufficiency and otherwise optimised 
glucocorticoid and mineralocorticoid replacement who suffer from low energy levels, impaired 
mood and decreased or absent libido. Single oral administration of 25-50 mg DHEA usually 
restores circulating androgen levels into the normal range. Monitoring comprises serum DHEAS, 
androstenedione, testosterone and SHBG 24 hours after the last morning dose, aiming at mid 
normal range levels. At present, studies on long-term outcomes of chronic DHEA 
supplementation in hypoadrenal women are lacking and are unlikely to be available soon as the 
steroid is widely available over the counter and the internet. 
 
Regenerating adrenal function 
Novel therapies beyond optimisation of steroid replacement therapy is a subject of current 
research and published approaches include immunosuppressive treatment in early stage 
Addison’s53 as well as attempts to achieve adrenal transplantation54. Most recently, a proof-of-
principle study showed re-emergence of adrenal function after continuous ACTH stimulation with 
depot synacthen in two patients with chronic Addison’s disease but minor residual function 55. 
 
Special therapeutic situations 
Various environmental, physiologic and pathologic conditions may influence replacement therapy 
in patients with adrenal insufficiency. Little evidence exists to suggest an optimal approach in 
these situations and the recommendations below represent expert opinion. 
Shift work or otherwise shifted daily routine (adolescents, students): We recommend changing 
the timing of steroid replacement according to the individual schedule (to take the larger dose of 
hydrocortisone on waking and the second dose in 6-8 hours after the first one). 
15 
 
Intensive exercise: Small carbohydrate meals before intense exercise bouts can be considered 56 
but are not mandatory and depend on individual response. Depending on the degree of physical 
activity and thus expected salt losses by sweating, the patient might benefit from a small dose 
increase in both glucocorticoid and mineralocorticoid, e.g. 2.5-5.0mg hydrocortisone every three 
hours during a marathon, and in a hot environment increasing fludrocortisone dose by 50-100µg 
per day to compensate for salt and water loss has been recommended57. 
Arterial hypertension: If a patient with primary adrenal insufficiency develops hypertension, the 
appropriateness of fludrocortisone dose should be checked; however, also Addison patients can 
develop essential hypertension. In this situation a slight reduction of fludrocortisone dose can be 
considered, tolerating slightly elevated renin levels, but mineralocorticoid treatment should not be 
stopped altogether and if needed, appropriate antihypertensive treatment should be established, 
preferably using calcium antagonists and alpha-blockers. ACE inhibitors and AT1R blockers are 
ineffective as the renin-angiotensin-aldosterone system is already disrupted.  
Diabetes mellitus: Newly developed type 2 diabetes should prompt consideration of the 
appropriateness of glucocorticoid dose. In patients with insulin-dependent diabetes mellitus, 
longer-acting glucocorticoids might help to achieve better glucose controls.  
Thyroid dysfunction: Hyperthyroidism increases cortisol clearance, thus thyrotoxic patients with 
adrenal insufficiency require higher hydrocortisone replacement doses. New onset 
hyperthyroidism can elicit an adrenal crisis; L-thyroxine replacement should only be initiated 
after hydrocortisone replacement has already been established. TSH levels <10mU/L in newly 
diagnosed Addison patients may not indicate hypothyroidism as TRH release physiologically 
requires inhibitory control by cortisol; therefore, TSH often normalises with hydrocortisone 
replacement alone. 
End-stage renal disease: In patients requiring dialysis, fludrocortisone is no longer needed and 
can be stopped; it is important to plan daily glucocorticoid replacement considering the fact that 
significant amounts of the morning glucocorticoid dose may be lost through haemodialysis. 
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Treatment and prevention of acute adrenal crisis 
Adrenal crisis represents a life-threatening emergency. Therefore, prevention is of key 
importance. The frequency of crisis has been reported as 6-8/100 patient years, with around a half 
of patients with Addison’s disease reporting at least one previous adrenal crisis 58, 59. Most 
frequent precipitating causes are gastroenteritis and fever (60-70%), but also other stressful events 
such as trauma, surgery, dental procedure and also major psychological distress 58, 59. Many crises 
result from failure to adjust glucocorticoid dose appropriately or at all; this is also caused to a 
significant degree by limited knowledge and slow reaction time of physicians involved in the 
acute care of adrenal insufficiency patients with incipient crisis59, 60. Patients with other 
comorbidities such as diabetes mellitus, diabetes insipidus, asthma and premature ovarian failure 
are at higher risk, but this does not sufficiently discriminate those patients with increased risk of 
adrenal crisis 58, 59. Symptoms include fatigue, nausea, vomiting, abdominal pain, muscle cramps, 
hypotension and can accelerate to hypovolaemic shock and coma. Hyponatraemia, hyperkalaemia 
and prerenal failure are frequently noted; hypoglycaemia is rarely observed in adults, but 
relatively frequent in children in whom it can significantly affect neurological outcome.  
Treatment includes prompt rehydration (1000ml of physiological saline in the first hour, 500 ml 
in the second hour followed by continuous fluid administration) and immediate parenteral 
administration of 100 mg hydrocortisone, followed by 200mg/24h, ideally per continuous i.v. 
infusion, alternatively in three to four daily doses per i.v. or i.m. injection. Patients require 
monitoring of vital signs and regular assessment of serum electrolytes. If clinically stable, 
glucocorticoid dose can be quickly tapered to the normal maintenance dose over 24-72 hours. 
Mineralocorticoid administration should be initiated as soon as total daily hydrocortisone dose is 
less than 50mg 25.  
Adequate prevention and treatment of adrenal crisis are of highest importance to avoid fatal 
outcomes. As adrenal insufficiency is a rare disease, many physicians are not familiar with its 
management often resulting in critical delays in emergency treatment. Education of patients and 
17 
 
relatives must provide information on correct adjustment of glucocorticoid replacement (sick day 
rules), symptom awareness, and steroid emergency card and medical alert bracelets (Table 2). 
The development and Europe-wide roll out of a steroid emergency card aiming to encourage the 
treating physician to immediately administer hydrocortisone in case of imminent crisis is 
currently under way.  
Emergency self-administration of hydrocortisone is of key importance to prevent crisis-related 
morbidity and mortality. In a 2006 survey 66% of Addison patients reporting a crisis had relied 
on medical personnel to administer the first treatment; only 12% of patients self-administered a 
hydrocortisone injection, with another 17% treated by a close person. Almost a third of patients 
did not have an emergency injection kit 58. As an alternative to intramuscular injection, which 
some patients are hesitant to administer promptly, subcutaneous injections might be an 
alternative, generating similar pharmacokinetics to intramuscular injection61. Suppositories 
containing 100 mg of prednisolone can be used based on patient’s preference62. Progress in this 
area will be achieved once pharmaceutical companies make progress in the development of a 
suitable self-injection device similar to the epinephrine auto-injector for patients with 
anaphylaxis. 
 
FERTILITY AND PREGNANCY 
Women with Addison’s disease have reduced rates of fertility, even after exclusion of women 
with premature ovarian failure63, 64. An increased risk of miscarriage has also been reported. 
Women with Addison’s disease also suffer higher rates of preterm birth and Caesarean delivery 
and more likely to have newborns with low birth weight (<2500g) 64. While women with adrenal 
insufficiency due congenital adrenal hyperplasia may often require Caesarean delivery, if there 
was previous genital correction surgery, other women with adrenal insufficiency should not 
require Caesarean delivery any more frequently than women in the normal population. 
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Physiologically, total cortisol concentrations are 2-3 times increased in pregnancy65, rising in the 
first trimester due to higher CBG levels and increased cortisol half-life secondary to decreases in 
hepatic clearance of the bound hormone66. However, from the 22nd week of gestation onwards 
also free cortisol levels increase significantly, most likely due to increased placental production of 
CRH. This results in hypertrophy of adrenal glands and increased responsiveness to synacthen as 
the pregnancy progresses 35, 67, with diagnostic and therapeutic implications.  
Adrenal insufficiency symptoms overlap with symptoms that might be related to pregnancy itself, 
such as fatigue, hyponatraemia, nausea and vomiting. The short synacthen stimulation test 
remains the test of choice in pregnant women if adrenal insufficiency is suspected. In a small 
cohort of healthy pregnant women the peak total cortisol response after ACTH injection was 
significantly higher in comparison to the non-pregnant state (median of 1000 nmol/L (37 µg/dl) in 
the second and third trimester  versus 700 nmol/L (26 µg/dl) postpartum) 35. Thus, it is prudent to 
use higher total cortisol cut-offs for confirming a diagnosis of adrenal insufficiency until more 
data is available; diagnostic cut-offs of 700nmol/L (25µg/dl), 800nmol/L (29µg/dl) and 
900nmol/L (32µg/dl) for the first, second and third trimester, respectively, have been 
recommended68. Although adrenal crisis due to failing to adapt the dose of glucocorticoid during 
pregnancy has been reported59, little evidence exists on the optimal glucocorticoid replacement 
during pregnancy84. Our usual practice is to increase hydrocortisone dose by around 20-40% 
during the third trimester to reflect the physiologic increase in free cortisol.  
Clinical assessment of mineralocorticoid requirements during pregnancy is difficult, again due to 
overlapping unspecific symptoms, such as oedema or postural hypotension. Sodium and 
potassium can be monitored in blood and urine; however plasma renin is not informative as levels 
physiologically increase during pregnancy. Increasing progesterone levels during pregnancy exert 
an anti-mineralocorticoid effect, thus it is sometimes required to adjust fludrocortisone dose69.  
During delivery hydrocortisone replacement should be similar to that in major surgical stress; 
100mg hydrocortisone i.v. at the onset of active labour (cervix 4 cm and/or contractions every 5 
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min for one hour), followed by hydrocortisone 200mg/24h per continuous i.v. infusion (or 50mg 
hydrocortisone i.v. or i.m. every six hours) until after delivery; thereafter, hydrocortisone can be 
quickly tapered back to pre-pregnancy doses within two to four days57. 
 
SUBJECTIVE HEALTH STATUS  
Patients with both primary and secondary adrenal insufficiency report reduced quality of life 
(QoL) in comparison to healthy controls; this is still observed even in patients with isolated 
adrenal insufficiency without any comorbidity. This finding corresponds with a higher level of 
working disability compared to the general population3, 4, 70 It has been shown that an inverse 
relationship of QoL and the age of adrenal insufficiency onset exists . Female sex, comorbidities 
and a delayed diagnosis of adrenal insufficiency were also noted as risk factors for decreased 
QoL17. The reduction in QoL despite established replacement therapy might be related to 
glucocorticoid over- or under-replacement, non-physiological circadian cortisol pattern generated 
by the currently available hydrocortisone preparations71, 72 or to lack of adrenal androgen 
replacement48, 51, indicating in principle an urgent need for improved replacement strategies73. In 
retrospective analyses, QoL was negatively correlated with the glucocorticoid dose and was still 
reduced in patients receiving DHEA replacement70. This suggests that non-physiological 
glucocorticoid replacement may play a major role. A small study restoring the circadian profile 
by administration of hydrocortisone via insulin pump demonstrated an increase of QoL74. 
Convincing data on optimal interventions in order to improve QoL however, is still lacking 
despite growing interest.  
 
PROGNOSIS 
In general, the prognosis for appropriately diagnosed and treated patients with adrenal 
insufficiency is good. However, it remains a potentially lethal condition and adrenal crisis 
remains one of the frequent causes of death, in particular in younger patients75. Standardized 
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mortality rates are more than double that of the age and sex adjusted control population in both 
primary and secondary adrenal insufficiency patients5, 76-78. Increased mortality in primary adrenal 
insufficiency is linked to increased rate of mainly respiratory infections 77 and, in particular in 
patients <40 years, also to adrenal crisis and sudden death75.   
In clinical practice, a significant proportion of patients regularly take replacement doses that are 
in excess of normal physiological levels, often to try to alleviate many of their symptoms. In 
addition, previous over-estimates of physiological cortisol production rates may have led to 
prescribed doses in excess of physiological requirements79. Furthermore, patients often take extra 
doses of hydrocortisone. For example, 52% of patients with adrenal insufficiency reported taking 
extra doses 1-3 times a month and 20% took extra doses more often4. Supraphysiological 
glucocorticoid replacement is associated with increased mortality80, cardiovascular risk and bone 
fragility. There is a clear HC dose response with BMI, triglyceride and total and LDL cholesterol 
concentrations in hypopituitary patients. However, all patients taking 20mg or less of HC per day 
had metabolic profiles similar to those with intact HPA axis81. A higher prevalence of central 
adiposity, impaired glucose tolerance and dyslipidaemia has been observed in patients with 
Addison’s disease taking 30mg hydrocortisone82. Interestingly, a more adverse metabolic 
response was noted when hydrocortisone was administered in the evening83. Studies have also 
shown an increased incidence of osteoporosis in patients receiving >30 mg of HC or 7.5 mg 
prednisone per day 43, 84 and an increased risk of fractures in Addison patients85. However, 
currently recommended replacement doses of 15-25 mg per day do not affect bone density86. 
 
In conclusion, despite significant advances over the last decade, the diagnosis and management of 
adrenal insufficiency still presents challenges and requires consideration of special situations to 
tailor replacement therapy to the individual patient. Raising awareness and education of both 
medical teams and patients on adrenal insufficiency and management of adrenal crisis is of 
paramount importance to improve clinical outcome. It remains to be demonstrated whether 
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modified release hydrocortisone preparations will provide a novel avenue for more physiologic 
replacement able to improve quality of life and prevent metabolic consequences. 
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Figure legend 
 
Figure 1: Diagnostic algorithm for adults with clinical signs and symptoms suggestive of adrenal 
insufficiency. Diagnostic measures should never delay the initiation of hydrocortisone treatment 
in suspected adrenal crisis. 
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